Targeted drug delivery by topical application

Funding Activity

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Drugs are applied to the skin for the treatment of a wide range of conditions, including both local (eg. inflammation, muscle pain, eczema, psoriasis and other dermatological conditions) and systemic (eg. angina, hormone replacement, nicotine withdrawal) therapies. Advances in molecular biology technology has also led to the development of a range of large molecular weight peptide and protein based therapeutic agents for which transdermal delivery offers the most cost-effective and practical solution if appropriate delivery systems can be identified. In addition, unwanted skin absorption also occurs following exposure to environmental occupational chemicals, and those applied deliberately to the skin such as insecticides, sunscreens and cosmetics. This study continues our work in seeking to define the relationship between the chemical structure of agents, the types of formulations and solvents in which they are applied or come into contact with the skin and their penetration, distribution and retention in the various layers of the skin and underlying tissues. Of great significance to both the pharmaceutical industry and risk assessment regulatory bodies will be the further development of our work into important areas relating to the ability to predict the likely behaviour of a solute following contact with the skin from the aspect of both optimising drug delivery systems and the accuracy of risk assessment procedures. We will also be continuing our work examining techniques to facilitate drug transport through the skin using physical techniques such as iontophoresis and the design of formulations to specifically target larger pores in the skin such as hair follicles as a means of improving delivery rates and increasing the range of solutes, particularly those of large molecular weight, likely to be considered as potential drug candidates.

Funded Activity Details

Start Date: 01-01-2005

End Date: 01-01-2007

Funding Scheme: NHMRC Project Grants

Funding Amount: $537,000.00

Funder: National Health and Medical Research Council